MedTrace Logo

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

NCT00135876 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 512

Last updated 2007-04-27

No results posted yet for this study

Summary

In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of VTE.

Conditions

Interventions

DRUG

dalteparin

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Ontario Clinical Oncology Group (OCOG)

    lead OTHER

Principal Investigators

  • James Perry, MD · Toronto Sunnybrook Regional Cancer Centre

  • Mark Levine, MD · Ontario Clinical Oncology Group (OCOG)

  • William Geerts, MD · Toronto Sunnybrook Regional Cancer Centre

  • Jim Julian, MMath · McMaster University, Dept of Clinical Epidemiology & Biostatistics

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Completion
2006-11-30

Countries

  • United States
  • Australia
  • Canada
  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00135876 on ClinicalTrials.gov